IP Library Granted Patent US 9,347,090
Granted Patent B2
US 9,347,090 · App. 13/962,637 · Granted May 24, 2016

Method for determining severity and progression of periodontal disease

Inventors: Kenneth Kornman (Waltham, MA); Xiaodong Wu (Needham, MA); Hwa-Ying Wang (Palo Alto, CA); John Rogus (North Andover, MA)
Assignee: Interleukin Genetics, Inc.
C12Q1/6827C12Q1/6883C12Q2600/156C12Q2600/172G01N2800/18
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,347,090
App. No.
13/962,637
Granted
May 24, 2016
Kind
B2
Abstract

An improved method and kit of determining whether a patient is predisposed to having severe periodontal disease and/or having high risk of progression of periodontal disease, comprising the steps of (i) taking a biological sample from said patient; (ii) genotyping said biological sample for genetic polymorphism pattern comprising IL 1B (rs16944), IL 1B (rs1143623) and IL 1B (rs4848306); and (iii) comparing said genetic polymorphism patterns to a reference composite genotype pattern; wherein the similarity of said genetic polymorphism patterns to said reference pattern indicate said patient's predisposition to having severe periodontal disease and/or having high risk of progression of periodontal disease.

Claims (29)

1. A method comprising the follow steps:

(i) obtaining a biological sample from a patient who does not have severe periodontal disease;

(ii) isolating a nucleic acid sample from said biological sample;

(iii) contacting said nucleic acid sample with oligonucleotide primers that hybridize 5′ and 3′ to each of the following single nucleotide polymorphisms (SNPs) in the IL1B gene: rs16944 C/T; rs1143623 G/C; and rs4848306 C/T;

(iv) amplifying nucleic acid in said nucleic acid sample with said oligonucleotide primers to produce one or more amplified fragments, wherein each of said SNPs is included in at least one of said one or more amplified fragments;

(v) detecting the number of copies of allele 1 and allele 2 of each of said SNPs in said one or more amplified fragments, wherein as a result of said detecting, the presence of one of the following composite genotypes is detected in said patient:

a) one copy rs16944 allele 1 (C), one copy rs1143623 allele 1 (G), and two copies of rs4848306 allele 1 (C);

b) two copies of rs16944 allele 2 (T), one copy of rs1143623 allele 1 (G), and two copies of rs4848306 allele 1 (C);

c) two copies of rs16944 allele 1 (C), two copies of rs1143623 allele 1 (G), and two copies of rs4848306 allele 1 (C);

d) one copy of rs16944 allele 1 (C), two copies of rs1143623 allele 1 (G), and two copies of rs4848306 allele 1 (C);

e) two copies of rs16944 allele 2 (T), two copies of rs1143623 allele 1 (G), and two copies of rs4848306 allele 1 (C); and

(vi) treating the patient of step (v), in whom one of the composite genotypes a)-e) has been detected, with a treatment regimen to slow down the progression of periodontal disease.

2. A method comprising the follow steps:

(i) obtaining a biological sample from a patient who does not have severe periodontal disease;

(ii) isolating a nucleic acid sample from said biological sample;

(iii) contacting said nucleic acid sample with oligonucleotide primers that hybridize 5′ and 3′ to each of the following single nucleotide polymorphisms (SNPs) in the IL 1B gene: rs16944 C/T; rs1143623 G/C; rs4848306 C/T, and rs1143633 G/A;

(iv) amplifying nucleic acid in said nucleic acid sample with said oligonucleotide primers to produce one or more amplified fragments, wherein each of said SNPs is included in at least one of said one or more amplified fragments;

(v) detecting the number of copies of allele 1 and allele 2 of each of said SNPs in said one or more amplified fragments, wherein as a result of said detecting, the presence of one of the following composite genotypes is detected in said patient:

f) two copies of ID B rs16944 allele 1 (C), two copies of rs1143623 allele 1 (G), two copies of rs4848306 allele 2 (T), and two copies of rs1143633 allele 1 (G);

g) one copy of rs16944 allele 1 (C), two copies of rs1143623 allele 1 (G), one copy of rs4848306 allele 2 (T), and two copies of rs1143633 allele 1 (G); and

(vi) treating the patient of step (v), in whom one of the composite genotypes f) or g) has been detected, with a treatment regimen to slow down the progression of periodontal disease.

3. The method of claim 1 or claim 2 , wherein said patient is a smoker.

4. The method of claim 1 or claim 2 , wherein said amplifying in step (iv) comprises a polymerase reaction.

5. The method of claim 4 , wherein the polymerase reaction is PCR.

6. The method of claim 1 or claim 2 , wherein at least one of said oligonucleotide primers of step (iii) is a labeled oligonucleotide primer.

7. The method of claim 6 , wherein said labeled oligonucleotide primer comprises a radiolabel, an enzyme label, a fluorescent compound, a streptavidin, an avidin, a biotin, a magnetic moiety, an antigen, or an antibody moiety.

8. The method of claim 1 or claim 2 , wherein the detecting in step (v) comprises use of at least one allele-specific oligonucleotide.

9. The method of claim 8 , wherein said allele-specific oligonucleotide comprises a radiolabel, an enzyme label, a fluorescent compound, a streptavidin, an avidin, a biotin, a magnetic moiety, an antigen, or an antibody moiety.

10. The method of claim 1 or claim 2 , wherein the method comprises the use of a TaqMane® assay.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 26, 2022
From: SEAPORT DIAGNOSTICS, INC.
To: SAPPHIROS LABORATORIES LLC
Reel/Frame 060028/0276 →
CHANGE OF NAME Recorded May 26, 2022
From: ORIG3N, INC.
To: SEAPORT DIAGNOSTICS, INC.
Reel/Frame 060389/0510 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2017
From: INTERLEUKIN GENETICS, INC.
To: ORIG3N, INC.
Reel/Frame 044341/0018 →
RELEASE OF SECURITY INTEREST Recorded Nov 27, 2017
From: HORIZON TECHNOLOGY FINANCE CORPORATION
To: INTERLEUKIN GENETICS INC.
Reel/Frame 044511/0428 →
RELEASE OF SECURITY INTEREST Recorded Nov 27, 2017
From: HORIZON TECHNOLOGY FINANCE CORPORATION
To: INTERLEUKIN GENETICS, INC.
Reel/Frame 044511/0467 →
SECURITY INTEREST Recorded Apr 13, 2017
From: INTERLEUKIN GENETICS, INC.
To: HORIZON TECHNOLOGY FINANCE CORPORATION
Reel/Frame 042001/0331 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2013
From: KORNMAN, KENNETH; WU, XIAODONG; WANG, HWA-YING; ROGUS, JOHN
To: INTERLEUKIN GENETICS, INC.
Reel/Frame 031231/0568 →
Continuity (4)
Continuation 13316198 · Dec 9, 2011
Provisional Application 61421628 · Dec 9, 2010
Provisional Application 61452157 · Mar 13, 2011
Related Publication 20130337448A1 · Dec 19, 2013